FDA Grants Breakthrough Therapy Designation to Merck’s Sacituzumab Tirumotecan for EGFR-Mutated NSCLC

Spur Therapeutics Unveils SPR301: A Novel Gene Therapy for GBA1-Linked Parkinson’s Disease

M | O | C Cancer Care & Research Centre Achieves CAR-T Therapy Milestone

Aptose Biosciences Collaborates with NCI to Advance Tuspetinib in Precision Medicine Trials for AML and MDS

Novartis and PTC Therapeutics Forge $2.9 Billion Partnership for Huntington’s Drug PTC518

HCG and Accenture Partner to Transform Cancer Care with Advanced AI

GE HealthCare to Acquire Full Ownership of Nihon Medi-Physics, Expanding Molecular Imaging Leadership in Asia

Strand Life Sciences Unveils CancerSpot for Early Cancer Detection

Allink Biotherapeutics Secures $42 Million in Series A Financing to Accelerate Development of Next-Generation Oncology and Immunology Therapies

Apollo Cancer Centres Launch India’s First Lunglife Screening Programme for Early Detection of Lung Cancer

Agilus Diagnostics Unveils Claudin 18.2 Test: A Breakthrough in Cancer Care

Leqembi® Launched in South Korea for Early Alzheimer’s Disease Treatment

QIAGEN Expands QIAstat-Dx Operations with New Facility in Barcelona

SunAct Cancer Institute Partners with Abgentil Biomedical to Revolutionize Cancer Treatment in India

Dr. Reddy’s Launches Toripalimab in India for Advanced Nasopharyngeal Carcinoma

Home
/
update
/
details

Apollo Cancer Centres Launch India’s First Lunglife Screening Programme for Early Detection of Lung Cancer

NextEdge Admin

29 Nov 2024

2 min 22 sec

Apollo Cancer Centres (ACC) have launched India’s first Lunglife Screening Programme in Delhi, marking a significant advancement in the country’s healthcare landscape. This pioneering initiative focuses on the early detection of lung cancer, which constitutes 5.9% of all cancer cases and 8.1% of cancer-related deaths in India. Early diagnosis is crucial for improving survival rates and enhancing treatment outcomes, as highlighted by ACC experts.

The programme is tailored for high-risk individuals, including those aged 50-80 with a history of smoking, a family history of lung cancer, or those asymptomatic but vulnerable. It aims to identify lung cancer at a treatable stage, addressing a critical gap in India’s cancer care.

The screening process is comprehensive, involving consultations with pulmonologists, pulmonary function tests (PFTs), and advanced low-dose computed tomography (LDCT) scans. These LDCT scans detect early-stage lung cancer with minimal radiation exposure, ensuring patient safety.

Dr. Nikhil Modi, senior pulmonology consultant at ACC, emphasized the importance of early detection, noting that advanced LDCT technology offers high diagnostic precision. Dr. Manish Singhal, senior consultant in medical oncology, described the initiative as transformative in combating rising lung cancer cases by enabling timely and personalized interventions. Dr. SVS Deo, lead surgical oncology consultant, referred to lung cancer as a “silent killer,” stressing that early detection through this programme can significantly improve survival rates and treatment outcomes.

This initiative brings renewed hope to thousands, prioritizing early-stage interventions and redefining lung cancer care in India.